Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manas Ranjan Behera has a total of 151 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Increased mortality rate in patients with Takayasu arteritis is largely driven by early disease activity and damage: analysis of two cohorts

    by Swapnil Jagtap, Aysegul Avcu, Sandeep Balakrishnan, Manas Ranjan Behera, Neeraj Jain, Anuradha Singh, Manish Ora, Roopali Khanna, Haner Direskeneli, Fatma Alibaz-Oner, et al.

    Objective: To evaluate mortality risk and pre-treatment predictors of mortality in Takayasu arteritis (TAK). Methods: From two cohorts, outcomes at last visit (survival/mortality) were recorded. Standardized mortality ratios (SMR) were computed (indirect standardization to population death rates from India and Turkiye). Cox proportional hazards regression was used to estimate predictors of mortality [hazard ratios (HR) with 95%CI]. The final multivariable-adjusted models included significant predictors of mortality from initial analyses based on demographic features, disease activity, damage (VDI) and clinical features or arterial involvement. Random forest (RF) and gradient boosted machines (GBM) machine learning tree models were used to understand the relative contributions of covariates in the multivariable-adjusted regression models to mortality risk. Results: Among 529 patients with TAK [India, n = 310, Turkiye, n = 219, mean age at onset 29.12 years, 413 females], 54 deaths were recorded (29 out-of-hospital, 29/54 from cardiovascular disease, 10/54 from infections). Survival was 97.73%, 96.55%, 90.24% and 82.37% at 1, 2, 5 and 10 years, respectively. TAK was associated with increased mortality rate [SMR for India 35.88 (95%CI 24.41–50.94) and Turkiye 27.61 (95%CI 17.53–41.41)]. Higher baseline disease activity by ITAS2010 (HR 1.06), damage (HR 1.30), impaired renal function (HR 2.21) or abdominal aorta involvement (HR 2.03) significantly predicted mortality risk with good model discrimination accuracy (Harrell’s C-statistic 0.772). Both RF and GBM models identified baseline activity and damage scores as major drivers of mortality. New-onset vascular events were largely driven by baseline ITAS2010. Conclusion: Increased mortality rate in TAK is largely driven by disease activity and early damage.

  • Epidemiology and Outcomes of Extrapulmonary Invasive Fungal Infections After Kidney Transplantation in Northern India

    by Abdullah, Anupma Kaul, Rungmei Marak, Manas Behera, Narayan Prasad, Manas Patel, Dharmendra Bhaduaria, Ravi Kushwaha, Monika Yachha, Akash Mishra

    Background: Extrapulmonary invasive fungal infections (IFIs) in kidney transplant recipients (KTRs) are understudied, particularly in endemic, resource‐limited settings. This study evaluated the epidemiology, risk factors, and outcomes of extrapulmonary IFIs in KTRs in northern India. Methods: In this nested case‐control study of 1649 KTRs (2007–2022), microbiologically proven extrapulmonary IFI cases were identified from microbiology and histopathology databases. Results: Extrapulmonary IFI occurred in 67 KTRs (4.1%). Cryptococcosis (46.3%) and candidiasis (20.9%) were the predominant infections. The central nervous system was the most common site (44.8%), followed by the bloodstream (22.4%). The mean age was 46.78 years, and 85.1% were males. The median time to infection was 55 months posttransplant, and 79.1% of infections occurred beyond 1 year posttransplant. Median estimated glomerular filtration rate (eGFR) was 43 mL/min/1.73 m 2 , and acute graft dysfunction was present in 49.3% cases. Comorbidities included diabetes (44.8%), chronic renal allograft injury (59.7%), acute rejection (38.8%), bacterial infection (26.9%), and cytomegalovirus disease (13.4%). Diabetes (OR 2.27, p = 0.038) and methylprednisolone pulses for rejection (OR 3.19, p = 0.025) were independently associated with IFI. Infection‐related mortality was 35.8%; disseminated infection (HR 3.72, p = 0.020) and requirement for kidney replacement therapy (KRT) (HR 3.98, p = 0.011) independently predicted death. Note that, 5‐ and 10‐year patient survival was significantly lower in cases than in controls (74.1% and 48.3% vs. 92.3% and 74.9%; p = 0.008), whereas death‐censored graft survival was comparable. Conclusions: Extrapulmonary IFIs are late‐onset and commonly present as cryptococcal meningitis or candidemia. Diabetes and methylprednisolone pulses increase infection risk, while dissemination and KRT requirement predict mortality. image

  • Open Access

    Monocyte/Macrophage Subsets in the Peripheral Blood, Their Related Cytokines, and Circulating Markers of Fibrosis in Active Takayasu Arteritis and Longitudinal Changes Following Immunosuppressive Therapy

    by Tooba Qamar, Deeksha Singh, Ranjeet Chauhan, Sara Abid, Upendra Rathore, Able Lawrence, Manas Behera, Neeraj Jain, Manish Ora, Durga Misra

    Takayasu arteritis (TAK) is a rare, stenosing large vessel vasculitis characterised by arterial wall fibrosis. Longitudinal changes in circulating monocyte/macrophage populations, which drive both inflammation and fibrosis in TAK, have not been studied. Circulating monocyte/macrophage populations, related cytokines, and markers of fibrosis were evaluated longitudinally in active TAK and compared with healthy controls. Flow cytometry was performed on peripheral blood mononuclear cells to identify overall CD14+CD66b-, M1-like, and M2-like monocytes/macrophages. Serum M1-like (TNF-α, IL-1β, IL-6, IP-10, IL-12p40, IL-23) and M2-like cytokines (IL-1RA, IL-10, CCL17) and circulating proteins indicating arterial wall fibrosis [plasma hyaluronic acid (HA), procollagen-III aminoterminal propeptide (PIIINP), tissue inhibitor of metalloproteinase 1 (TIMP-1), serum transforming growth factor-beta (TGF-β)] were estimated using cytokine bead array or ELISA. Mann–Whitney U-test was used for unpaired analysis, and Wilcoxon matched-pairs signed-rank test for paired analysis; p<0.05 was considered statistically significant (after correction for multiple testing). Eighteen patients with active TAK and 8 age- and sex-similar healthy controls were recruited. Patients with active TAK had higher circulating overall, M1-like, and M2-like monocytes/macrophages than controls (p<0.001). M1-like cytokines TNF-⍺, IL-6, and IL-23, and M2-like cytokine IL-1RA were higher in active TAK than controls (p<0.001). Circulating markers of fibrosis HA and PIIINP were significantly elevated in active TAK than controls (p<0.05). Following immunosuppressive therapy, a significant decrease in overall and M1-like monocytes/macrophages and related cytokines (TNF-⍺, IL-1β, IL-6, IL-12p40, IP-10, IL-23) concomitant with an increase in M2-like monocytes/macrophages, related M2-like cytokines (IL-10, CCL17) and circulating markers of fibrosis (HA, TIMP-1, PIIINP, TGF-β) was observed (p<0.05). A transition from M1-like to M2-like monocyte/macrophage populations with an increase in circulating markers of fibrosis is seen in the peripheral blood following immunosuppressive therapy in active TAK. Future treatment strategies should evaluate a combination of anti-fibrotic agents with immunosuppressive therapy in TAK.


  • High prevalent early damage independently predicts future mortality in an inception cohort of Takayasu arteritis

    by Durga Prasanna Misra, Upendra Rathore, Tooba Qamar, Kritika Singh, Deeksha Singh, Ranjeet Singh Chauhan, Sara Abid, Rudrarpan Chatterjee, Able Lawrence, Amita Aggarwal, et al.

    Objectives: The objective of this study was to evaluate early damage, and its evolution and prognostic relevance in an inception cohort of patients with Takayasu arteritis (TAK) using the Large Vessel Vasculitis Index of Damage (LVVID). Methods: Baseline LVVID was scored in an inception cohort of TAK who were within 3 months of cohort entry, at 1 year, and at the last follow-up at or after 1 year. Levels of associations between initial LVVID scores and demographic characteristics, disease activity, and angiographic subtypes were evaluated. Hazard ratios (HRs) for mortality per point/quartile increase in baseline LVVID scores were calculated using Cox proportional hazards regression. Damage evolution from baseline to 1 year or last follow-up was assessed using the paired Student’s t test. Pre-treatment predictors of progression were assessed using logistic regression. Results: Of 199 patients (141 females; 54 paediatric-onset), 192/199 (96.5%) had damage (most often cardiovascular) as indicated by the LVVID at presentation, 112/114 (98.2%) at 1 year, and 126/130 (96.9%) at last follow-up. Initial LVVID was greater with active disease, Hata’s type V, or Goel’s cluster 1 angiographic subtypes. Higher baseline LVVID was consistently associated with increased mortality [crude HR per point increase 1.49 (95% CI 1.24–1.81) or per quartile increase in LVVID 1.92 (1.21–3.05)], despite adjustment for disease activity or angiographic subtype. Significant progression of LVVID was observed at 1 year (3.49 ± 2.01 vs 3.27 ± 1.86, P < 0.001) or at the last follow-up (3.73 ± 2.18 vs 3.28 ± 1.88 P < 0.001), and was predicted by active disease at presentation [ odds ratio (OR) 2.89] and glucocorticoid (OR 3.53) or immunosuppressant use (OR 3.52). Conclusion: Most patients with TAK had recordable early damage, which was associated with future mortality.


  • Phenotypic clusters of patients with Takayasu arteritis predict disease activity at presentation, damage and future vascular complications

    by Aysegul Avcu, Augustine Jose, Sachit Ganapathy, Fatma Alibaz-Oner, Chengappa Kavadichanda, Upendra Rathore, Rahul Joseph Rajeev, Molly Mary Thabah, Manas Ranjan Behera, Neeraj Jain, et al.

    Objective: To identify clusters of Takayasu arteritis (TAK) based on clinical features and their prognostic relevance. Methods: Using agglomerative hierarchical clustering, clusters were defined by phenotype at presentation from 564 patients with TAK from three cohorts from India and Türkiye. Angiographic involvement, disease activity and Vasculitis Damage Index (VDI) at presentation, initiation of glucocorticoids or immunosuppressive agents, requirement for vascular procedures, and new-onset vascular complications were compared between clusters [unpaired Student’s t-test or odds ratios (OR) with 95% CI]. Mortality rates [hazard ratios (HR) with 95%CI] were computed using Cox regression. Results: Three clusters were identified (1 and 2, with sub-clusters 2A and 2B). Cluster 2 was younger and comprised relatively fewer women than cluster 1. Clinical features and angiography in cluster 1 reflected more frequent involvement of the aortic arch and its branches as opposed to a greater involvement of the abdominal aorta and its branches in cluster 2. Cluster 2B more often had pan-aortic disease and left subclavian involvement than 2A. Fewer patients in cluster 2A were initiated on glucocorticoids [OR adjusted for centre (aOR) 0.51 (95% CI: 0.31, 0.83)] or immunosuppressants [aOR 0.35 (95% CI: 0.20, 0.60)] or developed new-onset vascular complications [aOR 0.22 (95% CI: 0.07, 0.74)] than in cluster 1. Cluster 2B had higher VDI (3.98) than clusters 1 (3.50) or 2A (2.46) and required more frequent vascular interventions than cluster 1 or 2A (aOR 1.73, 1.88, P < 0.05). Survival was similar across clusters [HR 2A vs 1: 0.99 (95% CI: 0.43, 2.29), 2B vs 1: 1.20 (95% CI: 0.84, 1.70)]. Conclusion: Phenotypic clusters of TAK reflected distinct angiographic involvement with prognostic implications.


  • Open Access

    Novel mutation patterns in children with steroid-resistant nephrotic syndrome

    by Narayan Prasad, Jeyakumar Meyyappan, Manoj Dhanorkar, Ravi Kushwaha, Kausik Mandal, Vamsidhar Veeranki, Manas Behera, Manas Patel, Brijesh Yadav, Dharmendra Bhadauria, et al.

    Background: Idiopathic nephrotic syndrome (NS) in children poses treatment challenges, with a subset developing steroid-resistant nephrotic syndrome (SRNS). Genetic factors play a role, yet data on paediatric SRNS genetics in India are scarce. We conducted a prospective study using whole-exome sequencing to explore genetic variants and their clinical correlations. Methods: A single-centre prospective study (October 2018–April 2023) enrolled children with SRNS, undergoing renal biopsy and genetic testing per institutional protocol. Clinical, histological, and genetic data were recorded. DNA isolation and next-generation sequencing were conducted for genetic analysis. Data collection included demographics, clinical parameters, and kidney biopsy findings. Syndromic features were evaluated, with second-line immunosuppressive therapy administered. Patient and renal outcomes are presented for patients with and without genetic variants. Results: A total of 680 paediatric NS patients were analysed, with 121 (17.8%) having SRNS and 96 consent to genetic analysis. 69 (71.9%) had early SRNS, 27 (28.1%) late. Among participants, 62 (64.58%) had reportable genetic variants. The most common were in COL4A genes, with 20 (31.7%) positive. Renal biopsy showed focal segmental glomerulosclerosis in 31/42 (74%) with variants, 16/28 (57.1%) without variants. Second-line immunosuppressions varied, with CNIs the most common. Outcomes varied, with partial or complete remission achieved in some while others progressed to ESRD. Conclusion: The study underscores the importance of genetic analysis in paediatric SRNS, revealing variants in 65.7% of cases. COL4A variants were predominant. Variants correlated with varied renal outcomes, highlighting potential prognostic implications. These findings emphasize the value of personalized approaches and further research in managing paediatric SRNS.


  • Open Access

    Outcome of Glomerular Disease Manifesting After Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2

    by Shuvam Roy, Anupma Kaul, Monika Yachha, Pallavi Prasad, Ravi S. Kushwaha, Manas Patel, Narayan Prasad, Manoj Jain, Manas Ranjan Behera, Anupma Kaul Sr.

    Introduction Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can upregulate the immune system and may contribute to glomerular disease (GD). Here, we describe a spectrum of GD that manifested following vaccination against SARS-CoV-2 (COVID-19 vaccinations). Material and methods This was a descriptive study of 10 cases enrolled between January 2021 and January 2023. Patients with biopsy-proven GD that manifested following COVID-19 vaccinations were included. Results We found 10 cases of biopsy-proven GD following the COVID-19 vaccination. This included five cases of minimal change disease (MCD), three cases of focal segmental glomerulosclerosis (FSGS), one case of C3 glomerulonephritis (C3GN), and one case of IgA nephropathy (IgAN). The pre-existing disease was found in the last two patients (IgAN and C3GN) who got unmasked following vaccination. We did not observe any relation between vaccine type (Covisheld; six cases vs. Covaxin; four cases) and GD. In most cases (8/10 cases, 80.0%), GD developed after a repeat dose (second or booster dose). The onset time following vaccination was typically less than a week, and even less following a repeat dose. Conclusion Post-vaccination GD can be either de novo or a flare-up of a pre-existing one. The onset time following vaccination was typically less than a week for both Covishield and Covaxin.

  • Open Access

    Prevalence, Predictors, and Prognosis of Serious Infections in Takayasu Arteritis: A Cohort Study

    by Durga Prasanna Misra, Upendra Rathore, Swapnil Jagtap, Prabhaker Mishra, Darpan R. Thakare, Kritika Singh, Tooba Qamar, Deeksha Singh, Juhi Dixit, Manas Ranjan Behera, et al.

    Objective: To describe the incidence, risk factors, and outcomes associated with serious infections in patients with Takayasu arteritis (TA).Methods: Serious infections, defined as infections resulting in hospitalization or death or unusual infections like tuberculosis, were identified from a cohort of patients with TA. Corticosteroid and disease-modifying antirheumatic drug (DMARD) use at the time of serious infection was noted. Demographic characteristics, clinical presentation, angiography, and disease activity at presentation, and the use of DMARDs during follow-up were compared between patients with TA with or without serious infections. Mortality in patients with TA who developed serious infections was compared to those who did not using hazard ratios (HR; with 95% CI).Results: Of 238 patients with TA, 38 (16%) had developed serious infections (50 episodes, multiple episodes in 8; 3 episodes resulted in death). Among the 38 initial episodes, 11/38 occurred in those not on corticosteroids and 14/38 in those not on DMARDs. Pneumonia (n = 19) was the most common infection, followed by tuberculosis (n = 12). Patients with TA who developed serious infections vs those who did not had higher disease activity at presentation (active disease 97.4% vs 69.5%, mean Indian Takayasu Arteritis Activity Score 2010 12.7 (SD 7.3) vs 10.2 (SD 7.0), mean Disease Extent Index in Takayasu Arteritis 11.2 (SD 6.1) vs 8.8 (SD 6.1) and were more frequently initiated on corticosteroids or DMARDs. HRs calculated using exponential parametric regression survival-time model revealed increased mortality rate in patients with TA who developed serious infections (HR 5.52, 95% CI 1.75-17.39).Conclusion: Serious infections, which occurred in the absence of immunosuppressive treatment in approximately one-fifth of patients with TA, were associated with increased mortality in patients with TA.


  • Renal artery involvement is associated with increased morbidity but not mortality in Takayasu arteritis: a matched cohort study of 215 patients

    by Darpan R. Thakare, Prabhaker Mishra, Upendra Rathore, Kritika Singh, Juhi Dixit, Tooba Qamar, Manas Ranjan Behera, Neeraj Jain, Manish Ora, Dharmendra Singh Bhadauria, et al.

    Background We analyzed differences in presentation and survival of Takayasu arteritis (TAK) with or without renal artery involvement (RAI) from a large monocentric cohort of patients with TAK. Methods Clinical and angiographic features were compared between TAK with versus without RAI, with bilateral versus unilateral RAI, and with bilateral RAI versus without RAI using multivariable-adjusted logistic regression. Inter-group differences in survival were analyzed [hazard ratios (HR) with 95% confidence intervals (95%CI)] adjusted for gender, age at disease onset, diagnostic delay, baseline disease activity, and significant clinical/angiographic inter-group differences after multivariable-adjustment/propensity score matching (PSM). Results Of 215 TAK, 117(54.42%) had RAI [66(56.41%) bilateral]. TAK with RAI or with bilateral RAI had earlier disease onset than without RAI (p < 0.001). Chronic renal failure (CRF) was exclusively seen in TAK with RAI. TAK with RAI (vs without RAI) had more frequent hypertension (p = 0.001), heart failure (p = 0.047), abdominal aorta (p = 0.001) or superior mesenteric artery involvement (p = 0.018). TAK with bilateral RAI (vs unilateral RAI) more often had hypertension (p = 0.011) and blurring of vision (p = 0.049). TAK with bilateral RAI (vs without RAI) more frequently had hypertension (p = 0.002), heart failure (p = 0.036), abdominal aorta (p < 0.001), superior mesenteric artery (p = 0.002), or left subclavian artery involvement (p = 0.041). Despite higher morbidity (hypertension, CRF), mortality risk was not increased with RAI vs without RAI (HR 2.32, 95%CI 0.61–8.78), with bilateral RAI vs unilateral RAI (HR 2.65, 95%CI 0.52–13.42) or without RAI (HR 3.16, 95%CI 0.79–12.70) even after multivariable adjustment or PSM. Conclusion RAI is associated with increased morbidity (CRF, hypertension, heart failure) but does not adversely affect survival in TAK. Key Points •Renal artery involvement in TAK is associated with chronic renal failure. •TAK with renal artery involvement more often have heart failure and hypertension. •Bilateral renal artery involvement (compared with unilateral) is more often associated with hypertension and visual symptoms. •Renal artery involvement is not associated with an increased risk of mortality in TAK.


  • Clinicopathologic characteristics and outcomes of late onset lupus nephritis: a single centre experience

    by Harshita Sharma, Anupma Kaul, Sourya Sourabh Mohakuda, Manas Ranjan Behera, D. S. Bhadauria, Vinita Agrawal, Vikas Agarwal, Narayan Prasad, Anshima Singh, Manas Ranjan Patel

    Systemic Lupus Erythematosus (SLE) occurs in the reproductive age group. Renal involvement occurs less frequently in late-onset SLE than in reproductive-age SLE patients. Here, we aimed to study the clinical, serological and histopathological characteristics of late-onset lupus nephritis (LN). Late-onset LN was defined as disease onset after 47 years of age, corresponding to the average menopausal age. Records of biopsy proven late-onset lupus nephritis patients diagnosed between June 2000 and June 2020 were reviewed. Late-onset LN constituted 53 of 4420 patients (1.2%) biopsied during the study period. Females represented 90.65% of the cohort. Mean age of the cohort was 49.5 ± 7.05 years at the time of SLE diagnosis while its renal presentation was delayed by median duration of 10 months (IQR 3–48 months). Renal failure was present in 28 patients (52.8%) with acute kidney injury (AKI) (28.3%, n = 15) as the most common presentation. On histopathological analysis, class IV was observed in 23 patients (43.5%), crescents were observed in one-third cases and lupus vasculopathy in 4 patients (7.5%). All patients received steroids. Majority of patients (43.3%; n = 23) received Euro lupus protocol for induction. On median follow up duration of 82 months, renal flares were noted in 9 patients (17%) and 8 patients (15.1%) became dialysis dependent. Among 11 patients (21%) with infectious complications, 7 patients (13.2%) suffered from tuberculosis. Infections caused three-fourth of the deaths. Late-onset lupus nephritis is rare and presents as renal failure in majority. Renal biopsy affects the clinical decision of judicious use of immunosuppression which is imperative due to high rate of infections in this cohort.